Merck Cash Flow from Investing Activities 2010-2025 | MRK

Merck annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2025. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
  • Merck cash flow from investing activities for the quarter ending March 31, 2025 was $-7.734B, a 45.08% decline year-over-year.
  • Merck cash flow from investing activities for the twelve months ending March 31, 2025 was $-17.845B, a 59.79% decline year-over-year.
  • Merck annual cash flow from investing activities for 2024 was $-7.734B, a 45.08% decline from 2023.
  • Merck annual cash flow from investing activities for 2023 was $-14.083B, a 183.93% increase from 2022.
  • Merck annual cash flow from investing activities for 2022 was $-4.96B, a 69.79% decline from 2021.
Merck Annual Cash Flow Investing
(Millions of US $)
2024 $-7,734
2023 $-14,083
2022 $-4,960
2021 $-16,421
2020 $-9,193
2019 $-2,529
2018 $4,314
2017 $2,679
2016 $-3,210
2015 $-4,758
2014 $-374
2013 $-3,148
2012 $-6,805
2011 $-2,890
2010 $-3,497
2009 $3,156
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $190.989B $64.168B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $717.806B 55.04
Johnson & Johnson (JNJ) United States $364.111B 15.06
AbbVie (ABBV) United States $325.053B 17.92
Roche Holding AG (RHHBY) Switzerland $248.931B 0.00
Novartis AG (NVS) Switzerland $231.500B 13.22
Sanofi (SNY) France $130.557B 12.48
Pfizer (PFE) United States $129.797B 7.11
Bayer (BAYRY) Germany $25.032B 5.10
Innoviva (INVA) United States $1.166B 12.22
Novo Nordisk (NVO) Denmark $0.000B 19.04